Hermes patellofemoral arthroplasty: Annual revision rate and clinical results after two to 20 years of follow-up

Patellofemoral arthroplasty with onlay prosthesis leads to higher rates of osteoarthritis progression than inlay design implants: a systematic review

“…Tegner score was reported by five studies [7, 12, 23, 30, 40]. Furthermore, Kujala score [42, 48, 50], Lysholm score [16, 42, 50], KOOS [1, 12, 38], SF‐12 and SF‐36 [1, 19, 38] UCLA [12, 30], MKS [19, 43], HKS [3], IKS [10], IKDC [23], AKP [10] and HSS‐PF [50] were also presented. A small difference in Lysholm score values between inlay and onlay designs has been reported at a median follow‐up period of 25.5 months (range not given), with the inlay group scoring slightly higher (66 ± 11 vs. 57 ± 22) [16].…”

“…Another weakness is the retrospective type of the majority of the included studies, which could have led to an unknown selection bias. Another important aspect is that there are no studies reporting at mid-and long-term follow ups regarding the new inlay type of prosthesis, meaning that safe conclusions, with regards to the clinical and functional [38] 16 HemiCap Wave 24.1 (6-34) 1 (6.3%) 0 (0.0%) Metcalfe [32] 558 Avon 180 (nm) 61 (10.9%) 61 (10.9%) Ajnin [2] 43 FPV 65 (30-119) 5 (11.6%) 6 (13.9%) Bohu [10] 30 Hermes 240 (nm) 9 (30.0%) 9 (30.0%) Imhoff [22] 24 HemiCap Wave 60 (nm) 0 (0.0%) 6 (25.0%) Rammohan [42] 103 Journey 60 (± 12, 24-108) 9 (8.7%) 2 (1.9%) Bernard [7] 153 Avon 60 (± 30) 9 (5.9%) 9 (5.9%) Pogorzelski [40] 62 HemiCap Wave 60 (± 25) 12 (19.4%) 12 (19.4%) Marullo [30] 120 Gender Solutions 84 (± 30, 24-142) 5 (4.2%) 1 (0.8%) outcomes, and the survivorship of this type of prosthesis should be drawn with all due caution. Lastly, many authors were consultants for the companies designing the type of prostheses investigated in the respective studies, which might have led to a conflict of interest.…”

Should we recommend patellofemoral arthroplasties to patients?

“…61 In conclusion, this review was aimed at providing patients and surgeons the most up-to-date evidence available on surgical treatment choices for 18% of patients affected with PFJ OA. 3 Patients prefer more information when making a final choice for treatment, particularly being able to understand the difference in risks between each option. 75 The review gives an insight to the treatment available for those young active PFJ OA patients who may be 'too young' , are commonly female, more willing to accept disability, and less willing to accept the risk of surgery.…”

Patellofemoral arthroplasty: expert opinion

“…The second and third generation PFA are reported to have satisfactory patient reported and functional outcomes and reduction in mechanical complications [ 2 , 4 , 11 , 28 ].…”